Alopecia Areata Market

Market Overview:

The 7 major alopecia areata markets are expected to exhibit a CAGR of 6.05% during 2024-2034.

The alopecia areata market has been comprehensively analyzed in IMARC's new report titled "Alopecia Areata Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Alopecia areata refers to a common autoimmune disorder that leads to hair loss on the scalp and other areas of the body. It usually occurs when the immune system mistakenly attacks hair follicles, which leads to tissue scarring and hair loss. This condition is characterized by the appearance of small, coin-sized, round patches on the scalp. Symptoms associated with the ailment include hair loss, itching, anxiety, exclamation point hairs, small dents in nails, etc. The diagnosis of alopecia areata is typically made by analysis of the patient’s clinical features, medical history, and physical exam. A trichoscopy, which is a quick, non-invasive, and easy-to-perform procedure that helps to detect subtle details and validate a correct diagnosis, is also adopted by several healthcare professionals. Various other diagnostic studies include blood workups, antinuclear antibody tests, C-reactive protein tests, biopsy, etc., to rule out other possible causes of underlying symptoms among patients.

The rising cases of autoimmune disorders in which the white blood cells attack hair follicles, resulting in their shrinkage and damage, are primarily driving the alopecia areata market. Additionally, the increasing prevalence of several associated risk factors, including genetic predisposition, injury, poor nutrition, comorbidities, severe emotional stress, etc., is also augmenting the market growth. Furthermore, the widespread adoption of immunosuppressant drugs, including methotrexate, cyclosporine, azathioprine, etc., which work by blocking the immune response that causes hair loss, is creating a positive outlook for the market. Apart from this, the inflating utilization of phototherapy for stimulating hair growth in patients and minimizing inflammation and itching is acting as another significant growth-inducing factor. Additionally, the escalating demand for hair implants that involve transplanting follicular grafts to the affected area in order to restore hair follicles and treat receding hairlines or spots of baldness is also bolstering the market growth. Moreover, the ongoing advancements in micro-needling techniques, since they stimulate neovascularization, hair bulge and the release of growth factors, are expected to drive the alopecia areata market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the alopecia areata market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for alopecia areata and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the alopecia areata market in any manner.

Recent Developments:

• In June 2024, Equillium Inc. reported positive topline results from its Phase 2 single-dose proof-of-concept (PoC) study of EQ101 in adult patients with moderate, severe, or very severe alopecia areata. The study's primary goals were to assess the safety and tolerability profile of EQ101, as well as efficacy indicators using Severity of Alopecia Tool (SALT) scores, where a score of 100 denotes entire scalp hair loss, and 0 represents no scalp hair loss.
• In October 2023, Sun Pharmaceutical Industries Ltd received FDA approval for deuruxolitinib, an oral selective inhibitor of Janus kinases JAK1 and JAK2, to treat moderate to severe alopecia areata in adults. Sun Pharma submitted an NDA for 8mg of deuruxolitinib twice daily for FDA assessment.
• In September 2023, Q32 Bio stated that the first patient had been dosed in a Phase 2 multicenter, randomized, double-blind, placebo-controlled proof-of-concept study with bempikibart in adult patients with severe alopecia areata. Q32 Bio and Horizon are working to develop bempikibart, a completely human anti-IL-7Rα antibody that re-regulates adaptive immune function by inhibiting signaling from both IL-7 and TSLP, two essential immune pathways.
• In June 2023, Pfizer Inc. stated that the United States FDA had approved LITFULO (ritlecitinib), a once-daily oral therapy for people aged 12 and above with severe alopecia areata. The approved recommended dose of LITFULO is 50 mg. It is the first and only FDA-approved medication for adolescents (12 and older) with severe alopecia areata.
• In June 2023, Legacy Healthcare announced that its Marketing Authorisation Application (MAA) for Coacillium for the management of moderate to severe alopecia areata in children and adolescents has been validated and is now being reviewed by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).

Key Highlights:

• The estimated lifetime prevalence of alopecia areata was 0.10% in the general population worldwide, 0.12% in adults, and 0.03% in children.
• The condition affects up to 6.7 million people in the United States alone.
• The prevalence of alopecia areata was greater among females (0.252%-0.271%) than males (0.145%-0.171%).
• The highest standardized prevalence was found among Asian patients (414 per 100,000).
• The frequency of alopecia areata appeared to be higher in persons aged 19-50 years.

Drugs:

OLUMIANT is a once-daily oral JAK inhibitor developed by Incyte and licensed to Lilly, and it is available at specialty pharmacies countrywide. OLUMIANT is used to treat adult patients with severe alopecia areata.

PF-06651600 is an oral small molecule that specifically inhibits Janus kinase (JAK) 3 for the management of alopecia areata. The JAK pathways are considered to play a key role in inflammatory processes because they signal for more than 50 cytokines and growth factors, many of which cause immune-mediated diseases.

CTP-543 is an experimental oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has designated CTP-543 as a Breakthrough Therapy for the treatment of adult patients with moderate to severe alopecia areata, as well as a Fast Track designation for alopecia areata.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the alopecia areata market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the alopecia areata market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current alopecia areata marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the alopecia areata market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the alopecia areata market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the alopecia areata market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of alopecia areata across the seven major markets?
• What is the number of prevalent cases (2018-2034) of alopecia areata by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of alopecia areata by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of alopecia areata by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with alopecia areata across the seven major markets?
• What is the size of the alopecia areata patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of alopecia areata?
• What will be the growth rate of patients across the seven major markets?
   

Alopecia Areata: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for alopecia areata drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the alopecia areata market?
• What are the key regulatory events related to the alopecia areata market?
• What is the structure of clinical trial landscape by status related to the alopecia areata market?
• What is the structure of clinical trial landscape by phase related to the alopecia areata market?
• What is the structure of clinical trial landscape by route of administration related to the alopecia areata market?